⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17628695 | 1.00 | — | — | |
| SCHEMBL27304398 | 0.75 | — | — | |
| Dichloroacetic Acid SCHEMBL5874642 | 0.73 | LMNA (0.71) | — | |
| SCHEMBL29080351 | 0.73 | — | — | |
| Hydrochloric Acid SCHEMBL27823106 | 0.73 | — | — | |
| SCHEMBL29129968 | 0.71 | — | — | |
| SCHEMBL28169467 | 0.71 | LMNA (0.40) | — | |
| SCHEMBL3895464 | 0.69 | — | — | |
| Water SCHEMBL29031573 | 0.69 | — | — | |
| SCHEMBL29080349 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4299064-A2 | TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY | THE CLEVELAND CLINIC FOUNDATION (US) | 2024-01-03 | — | — | EP | claimed |
| EP-3641748-B1 | TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY | CLEVELAND CLINIC FOUND (US) | 2023-11-29 | — | — | EP | claimed |
| EP-3197442-B1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | CLEVELAND CLINIC FOUND (US) | 2019-07-03 | — | — | EP | claimed |
| US-12576055-B2 | Disease detection and treatment based on trimethyl-lysine levels | THE CLEVELAND CLINIC FOUNDATION (US) | 2026-03-17 | — | — | US | disclosed |
| US-20240165131-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | THE CLEVELAND CLINIC FOUNDATION | 2024-05-23 | — | — | US | disclosed |
| US-20240139120-A1 | TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY | THE CLEVELAND CLINIC FOUNDATION | 2024-05-02 | — | — | US | disclosed |
| US-11911399-B2 | Treating and preventing disease with TMA and TMAO lowering agents | THE CLEVELAND CLINIC FOUNDATION (US) | 2024-02-27 | — | — | US | disclosed |
| EP-4299064-A2 | TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY | THE CLEVELAND CLINIC FOUNDATION (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-3641748-B1 | TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY | CLEVELAND CLINIC FOUND (US) | 2023-11-29 | — | — | EP | disclosed |
| US-11771659-B2 | Treating disease and promoting weight loss by inhibiting the TMA/FMO3/TMAO pathway | THE CLEVELAND CLINIC FOUNDATION (US) | 2023-10-03 | — | — | US | disclosed |
| US-20210186991-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | THE CLEVELAND CLINIC FOUNDATION | 2021-06-24 | — | — | US | disclosed |
| US-10933072-B2 | Treating and preventing disease with TMA and TMAO lowering agents | THE CLEVELAND CLINIC FOUNDATION (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200197417-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | THE CLEVELAND CLINIC FOUNDATION | 2020-06-25 | — | — | US | disclosed |
| US-20200121615-A1 | TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-04-23 | — | — | US | disclosed |
| EP-3569232-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | The Cleveland Clinic Foundation (US) | 2019-11-20 | — | — | EP | disclosed |
| US-20190038642-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | THE CLEVELAND CLINIC FOUNDATION | 2019-02-07 | — | — | US | disclosed |
| US-10117879-B2 | Treating and preventing disease with TMA and TMAO lowering agents | THE CLEVELAND CLINIC FOUNDATION (US) | 2018-11-06 | — | — | US | disclosed |
| US-20170266208-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | THE CLEVELAND CLINIC FOUNDATION | 2017-09-21 | — | — | US | disclosed |
| US-9694020-B2 | Treating and preventing disease with TMA and TMAO lowering agents | THE CLEVELAND CLINIC FOUNDATION (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160089387-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | THE CLEVELAND CLINIC FOUNDATION | 2016-03-31 | — | — | US | disclosed |